Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease
Roberta Ricciarelli, Chiara Brullo, Jos Prickaerts, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Connecting dots: Preclinical foundations to clinical realities of PDE4 inhibitors in Alzheimer's disease
Shilpa Kumari, Kajal Bagri, Rahul Deshmukh
Inflammopharmacology (2025)
Closed Access | Times Cited: 2
Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease
Jos Prickaerts, Pim R.A. Heckman, Arjan Blokland
Expert Opinion on Investigational Drugs (2017) Vol. 26, Iss. 9, pp. 1033-1048
Open Access | Times Cited: 157
Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets
Max Lam, Joey W. Trampush, Jin Yu, et al.
Cell Reports (2017) Vol. 21, Iss. 9, pp. 2597-2613
Open Access | Times Cited: 122
Advances in the Development of Phosphodiesterase-4 Inhibitors
Ting Peng, Baowen Qi, Jun He, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 19, pp. 10594-10617
Closed Access | Times Cited: 80
The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice
Hao Wang, Fangfang Zhang, Yong Xu, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 23, Iss. 10, pp. 700-711
Open Access | Times Cited: 70
The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors
Dean Paes, Melissa Schepers, Ben Rombaut, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 1016-1049
Open Access | Times Cited: 67
cAMP-PKA cascade: An outdated topic for depression?
Feng Gao, Shaojie Yang, Juan Wang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 113030-113030
Open Access | Times Cited: 51
Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis
Melissa Schepers, Dean Paes, Assia Tiane, et al.
Brain Behavior and Immunity (2022) Vol. 109, pp. 1-22
Open Access | Times Cited: 39
Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer’s disease
Paul Armstrong, Hüseyin Güngör, Pariya Anongjanya, et al.
Neuropsychopharmacology (2024) Vol. 49, Iss. 10, pp. 1559-1568
Open Access | Times Cited: 8
Phosphodiesterase inhibitors say NO to Alzheimer's disease
Seyed Mohammad Nabavi, Sylwia Talarek, Joanna Listos, et al.
Food and Chemical Toxicology (2019) Vol. 134, pp. 110822-110822
Closed Access | Times Cited: 67
Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice
Chong Zhang, Ying Xu, Anirudh Chowdhary, et al.
Neuropsychopharmacology (2018) Vol. 43, Iss. 11, pp. 2299-2309
Open Access | Times Cited: 66
Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations
Pim R.A. Heckman, Arjan Blokland, Eva Bollen, et al.
Neuroscience & Biobehavioral Reviews (2018) Vol. 87, pp. 233-254
Open Access | Times Cited: 65
Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study
Arjan Blokland, Marlies A. van Duinen, Anke Sambeth, et al.
Neurobiology of Aging (2019) Vol. 77, pp. 37-43
Open Access | Times Cited: 57
Phosphodiesterase Type 4 Inhibition in CNS Diseases
Arjan Blokland, Pim R.A. Heckman, Tim Vanmierlo, et al.
Trends in Pharmacological Sciences (2019) Vol. 40, Iss. 12, pp. 971-985
Open Access | Times Cited: 55
Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-β pathology
Dean Paes, Melissa Schepers, Emily Willems, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 7
Open Access | Times Cited: 18
Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous system
Zoë Donders, Iga Joanna Skorupska, Emily Willems, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117009-117009
Open Access | Times Cited: 7
Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases
Qi Li, Qinghong Liao, Shulei Qi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116386-116386
Closed Access | Times Cited: 6
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Rumiana Tenchov, Janet M. Sasso, Qiongqiong Angela Zhou
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 21, pp. 3800-3827
Open Access | Times Cited: 6
Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches
Amy J. Tibbo, Gonzalo S. Tejeda, George S. Baillie
Biochemical Society Transactions (2019) Vol. 47, Iss. 5, pp. 1557-1565
Open Access | Times Cited: 50
Role of cyclic nucleotides and their downstream signaling cascades in memory function: Being at the right time at the right spot
Elentina K. Argyrousi, Pim R.A. Heckman, Jos Prickaerts
Neuroscience & Biobehavioral Reviews (2020) Vol. 113, pp. 12-38
Open Access | Times Cited: 48
Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist
Giovanni Ribaudo, Alberto Ongaro, Giuseppe Zagotto, et al.
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 12, pp. 1726-1739
Open Access | Times Cited: 47
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease
Meiyang Xi, Tian‐Yu Sun, Shejie Chai, et al.
European Journal of Medicinal Chemistry (2022) Vol. 232, pp. 114170-114170
Closed Access | Times Cited: 24
PDE4D: A Multipurpose Pharmacological Target
Matteo Lusardi, Federica Rapetti, Andrea Spallarossa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8052-8052
Open Access | Times Cited: 5
Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A
Melissa Schepers, Tim Vangansewinkel, Karen Libberecht, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117828-117828
Open Access
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease
Jinhui Hu, Tingting Pan, Baijiao An, et al.
European Journal of Medicinal Chemistry (2018) Vol. 163, pp. 512-526
Closed Access | Times Cited: 43
Page 1 - Next Page

Scroll to top